Heart Failure

Pirfenidone vs. placebo in patients with HF, EF at least 45% and elevated natriuretic peptide levels.

Sacubitril/valsartan (Entresto, Novartis) vs. valsartan in patients with advanced HF.

Methamphetamine-related HF hospitalizations and their costs increased at an alarming rate compared with all HF hospitalization from 2008 to 2018, researchers reported.

Sharing results of genetic tests for cardiomyopathy with adolescents does not appear to negatively impact family functioning scores, researchers reported.

In this video perspective, Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, offers a review of the Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases workshop, held June 18 to 19 in Dallas.

Beta-blocker use at hospital admission for acute decompensated HF was associated with lower in-hospital mortality compared with nonuse before hospitalization, researchers reported.

Empagliflozin reduced CV death or HF hospitalization compared with placebo in patients with HF with preserved ejection fraction, regardless of diabetes status, according to topline results of the EMPEROR-Preserved trial.

HF severity objectively measured by ventilatory efficiency during exercise was more closely associated with all-cause death and hospitalization compared with subjective, patient-perceived measures of HF severity, researchers reported.

In patients with HF, evidence-based therapy was less utilized among patients aged 80 years and older compared with younger patients, according to new data.

The dual SGLT1/SGLT2 inhibitor sotagliflozin is effective at reducing risk for heart failure, myocardial infarction and stroke while also slowing progression of chronic kidney disease, according to findings from two large clinical trials.